Free press releases distribution network?

Agency / Source: Report Buyer Ltd

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!



Safety Concerns Prompt FDA to Negatively Review Genentech-Roche's Avastin® for Breast Cancer - Report Buyer, the online destination for business intelligence for major industry sectors, has added a report which finds that an FDA advisory panel has said that Genentech/Roche's Avastin® should not receive FDA approval for metastatic breast cancer
Safety Concerns Prompt FDA to Negatively Review Genentech-Roche's Avastin® for Breast Cancer

 

PRZOOM - /newswire/ - London, United Kingdom, 2008/01/25 - Report Buyer, the online destination for business intelligence for major industry sectors, has added a report which finds that an FDA advisory panel has said that Genentech/Roche's Avastin® should not receive FDA approval for metastatic breast cancer.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Report Buyer, the online destination for business intelligence for major industry sectors, has added a new report which finds that an FDA advisory panel has suggested that Genentech/Roche's Avastin® should not receive FDA approval for metastatic breast cancer.

“Pipeline Insight: Molecular Targeted Cancer Therapies - Can anything else revolutionize the market?” finds that as the FDA usually follows the panel's recommendation, concerns were raised over the drug's future. It however, states that a number of reasons may still drive US approval of the drug in metastatic breast cancer.

Genentech/Roche's anti-angiogenic, monoclonal antibody Avastin® (Bevacizumab) was given a negative recommendation for metastatic breast cancer over safety concerns and the panel's decision sent Genentech's shares to a two-and-a-half year low. The drug's fate now lies in the hands of the FDA, which will consider the panel's recommendation in deciding whether to grant Avastin approval for metastatic breast cancer.

The report says Avastin was the first anti-angiogenesis inhibitor to enter the oncology market. It finds that Genentech, majority-owned by Roche, holds Avastin's marketing rights in the US, where the drug made sales of $1.7 billion in the first nine months of 2007. Avastin has been approved in the US and EU for the first-line treatment of metastatic colorectal cancer and in the US for the treatment of non-small cell lung cancer. In March 2007, Avastin was approved in the EU for the first-line treatment of metastatic breast cancer in combination with the standard chemotherapy paclitaxel.

Analysts say that in Avastin's pivotal study in metastatic breast cancer, 722 patients received paclitaxel or paclitaxel in combination with Avastin. Avastin was shown to extend progression-free survival by 5.5 months, but not overall survival. However, patients in the Avastin group were found to have a 20% increase in serious side effects including hypertension, blood clots and heart attacks.

Authors of the report find that in the drug's recent review, FDA staff suggested that the improvement in progression-free survival should be weighted against the potentially fatal toxicity. The FDA, which usually follows the advisory panel's advice, will now consider the panel's negative recommendation in deciding whether to approve Avastin for breast cancer.

The study clarifies that Avastin is already used off-label in the US for metastatic breast cancer. However, FDA approval would allow the drug to be promoted for this indication and help in reimbursement for insurers. If approval is granted, Avastin is expected to change the first-line treatment of metastatic breast cancer.

The publication states that despite ODAC's negative recommendation and despite its questionable toxicity profile, the FDA is likely to approve Avastin even though it only achieved an incremental improvement in progression-free survival. Avastin's approval in the EU for breast cancer, its extensive off-label use in breast cancer in the US, and the high patient and physician awareness may all force a positive FDA decision.

“Pipeline Insight: Molecular Targeted Cancer Therapies - Can anything else revolutionize the market?” is available from Report Buyer. For more information, please visit the website.

Report Buyer product ID: DAT08284

About Report Buyer
Report Buyer is a UK-based independent online store supplying business information on major industry sectors. These include the Automotive Industry, Banking & Finance, Energy & Utilities, Food & Drink, Telecoms and Pharma & Healthcare. The website now carries over 40,000 business information products, including market reports, studies and books. Report Buyer is the intelligent way to buy market research making it an essential resource for executives and information buyers worldwide. Subscribers receive a free monthly newsletter and email alerts on new titles in their areas of interest. A regularly updated blog provides information on the latest market trends.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Agency / Source: Report Buyer Ltd

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick PRZOOM - Press & Newswire Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Safety Concerns Prompt FDA to Negatively Review Genentech-Roche's Avastin® for Breast Cancer

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name PRZOOM - Press & Newswire and LINK as the source.
 
  For more information, please visit:
Is this your article? Activate ALL web links by Upgrading to Press Release PREMIUM Plan Now!
|
Contact: Urmila Doraswami 
+44 (0) 20 7060 7474 press[.]reportbuyer.com
 
PRZOOM / PRTODAY - Newswire Today disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Report Buyer Ltd securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!




Read Latest Press Releases From Report Buyer Ltd / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Press Releases:

Ipsen Announces Phase 3 CELESTIAL Trial of Cabozantinib Meets Primary Endpoint of Overall Survival
First Patient Treated with Microscopic Beads Pre-loaded with A Targeted Cancer Drug and Visible on CT Scans
BTG Plc Acquires Roxwood Medical
BTG and Mirada Medical Sign Three-Year Software Development Agreement
U.S. FDA Approves New Indication for Ipsen’s Somatuline® Depot (lanreotide) Injection for the Treatment of Carcinoid Syndrome
Genentech Provides Update on First Lampalizumab Phase III Study for Geographic Atrophy, an Advanced Form of Age-Related Macular Degeneration
mProve Health and Greenphire Partner to Deliver a First-of-its-Kind Patient Engagement Solution
FDA Approves Genentech’s Actemra (Tocilizumab) for the Treatment of CAR T Cell-Induced Cytokine Release Syndrome
Greenphire Named to Inc. 5000 for Fifth Consecutive Year
Five Community Health Centers Honored for Innovative Approaches to Medication Therapy Management

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
 
NewswireToday Celebrates 10 Years in Business
Find business coaching, life coaching, executive coaching and corporate coaching, best selling coaching books, ...



PREMIUM Members


Visit  JobsWare.com

Visit  BizJobs.com

Visit  RightITnow Ltd







 
  ©2017 PRZOOM — Limelon Advertising, Co.
Home | About PRZOOM | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneur newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today